CytomX Therapeutics, Inc. CTMX
2.70
(0.05)
(1.82%)
as of 25 Sep
- Market cap
- $599.2M
- P/E
- 0.0×
Follow CTMX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| ROE |
+8 more TTM periods Free account |
66.76% | (41.34%) | (36.03%) | (39.18%) |
| ROA | 18.85% | (14.97%) | (27.15%) | (29.72%) | |
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% | |
| Return on Tangible Assets | 25.49% | (20.66%) | (19.41%) | (24.72%) | |
| Average Days of Receivables | 5.23 | 9.64 | 6.63 | 747.75 | |
| Free Cash Flow per Share | (0.44) | (0.55) | (0.45) | (0.38) | |
| Free Cash Flow | (72.35) | (75.81) | (80.09) | (82.41) | |
| Capital Expenditures | (0.10) | (0.22) | — | — | |
| Piotroski F-Score | 4.00 | 1.00 | 1.00 | 2.00 | |
| Other line items | |||||
| Cash ROIC | (28.78%) | (32.02%) | (12.01%) | (13.01%) | |
| Accounts Receivable Turnover | 45.63 | 29.79 | 27.32 | 0.93 | |
| Accounts Payable Turnover | 0.00 | 0.00 | 0.00 | 0.00 | |
| Average Days of Payables | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax Rate | (0.01) | 0.01 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 54.81% | 90.19% | 194.41% | 400.91% | |
| Selling, General and Administrative Expense of Revenue | 24.73% | 39.16% | 87.50% | 175.28% | |
| Share Based Compensation of Revenue | 5.90% | 8.27% | 25.32% | 55.44% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | (2.58) | 3.71 | 1.29 | 1.00 | |
| Depreciation/Fixed assets | (0.58) | (0.64) | (1.13) | (2.38) | |
| Capex/Depreciation | 0.10 | 0.27 | 0.00 | 0.00 | |
| Revenue per Share | 0.69 | 0.55 | 0.20 | 0.08 | |
| Operating CF per Share | (0.44) | (0.55) | (0.45) | (0.38) | |
| Capex per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | 24.66% | (26.73%) | (174.84%) | (451.62%) |
Columns are period end dates